An International Journal of Otorhinolaryngology Clinics

Register      Login

VOLUME 2 , ISSUE 1 ( January-April, 2010 ) > List of Articles

REVIEW ARTICLE

Chemotherapy and Biologic Therapy for Squamous Cell Cancers of the Head and Neck

Sameer Mahesh

Keywords : cetuximab,chemotherapy,Head and neck cancer

Citation Information : Mahesh S. Chemotherapy and Biologic Therapy for Squamous Cell Cancers of the Head and Neck. Int J Otorhinolaryngol Clin 2010; 2 (1):33-41.

DOI: 10.5005/jp-journals-10003-1015

Published Online: 00-04-2010

Copyright Statement:  Copyright © 2010; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Squamous cell carcinoma of the head and neck presents a treatment challenge owing to the complexity of the anatomy of the head and neck region. Till recently, tobacco and alcohol were thought to be the main risk factors. Recently, human papilloma virus (HPV) has gained significant attention in the etiology of oropharyngeal cancer. Depending on the location of the tumor, surgery as a primary treatment can be quite debilitating due to cosmetic as well as functional reasons. Nonsurgical (radiotherapy or chemoradiotherapy) modalities are preferred as initial treatments of oropharynx, hypopharynx and larynx primaries. A multidisciplinary approach is recommended for treatment of these malignancies.


PDF Share
  1. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350(19):1945–52.
  2. Postoperative concurrent radiotherapy and chemotherapy for high-risk squalors-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937–44.
  3. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005;27(10):843–50.
  4. A randomized EORTC study on the effect of preoperative polychemotherapy in pyriform sinus carcinoma treated by pharyngolaryngectomy and irradiation. Results from 5 to 10 years. Acta Chir Belg 1990;90(3):115–22.
  5. Induction chemotherapy in advanced head and neck tumors: Results of two randomized trials. Int J Radiat Oncol Biol Phys 1992;23(3):483–89.
  6. Induction chemotherapy in head and neck cancer: Results of a phase III trial. Head Neck 1992;14(2):85–91.
  7. Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer. Oncology 1993;(50 Suppl)2:23–27.
  8. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst, 1994;86(4):265–72.
  9. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000;83(12):1594–98.
  10. Primary chemotherapy in resectable oral cavity squamous cell cancer: A randomized controlled trial. J Clin Oncol, 2003;21(2):327–33.
  11. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88(13):890–99.
  12. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355(9208):949–55.
  13. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17):1695–704.
  14. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357(17):1705–15.
  15. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324(24):1685–90.
  16. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349(22):2091–98.
  17. Randomized trial of radiation therapy vs concomitant chemotherapy and radiation therapy for advancedstage oropharynx carcinoma. J Natl Cancer Inst 1999;91(24): 2081–86.
  18. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996;88(9):583–89.
  19. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338(25):1798–804.
  20. Simultaneous radiochemotherapy vs radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 1998;16(4):1318–24.
  21. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000;88(4):876–83.
  22. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21(1):92–98.
  23. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 2000;18(7):1458–64.
  24. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10(2):257–63.
  25. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116–27.
  26. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) vs CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). Journal of Clinical Oncology 2009;27(15s):Abstract 6009.
  27. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90(11):824–32.
  28. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24(25):4170–76.
  29. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007;25(16):2164–70.
  30. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005;1:2005 0010.
  31. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1(11):1311–18.
  32. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7(4):301–11.
  33. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007;98(8):1275–80.
  34. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006;354(6):567–78.
  35. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes. Radiother Oncol 2009;90(2):166–71.
  36. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008;19(1):142–49.
  37. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23(34):8646–54.
  38. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25(16):2171–77.
  39. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21(10):1980–87.
  40. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22(1):77–85.
  41. Phase III study of gefitinib 250 compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27(11):1864–71.
  42. Chemoradiotherapy vs radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 1998;16(4):1310–17.
  43. Overall survival after concurrent cisplatinradiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97(7):536–39.
  44. Phase III study of concurrent chemoradiotherapy vs radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival. J Clin Oncol 2003;21(4):631–37.
  45. B Combined chemoradiation vs radiation therapy alone in locally advanced nasopharyngeal carcinoma: Results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 2002;25(3):219–23.
  46. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data metaanalysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006;64(1):47–56.
  47. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995;33(3):569–77.
  48. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 2005;23(6):1118–24.
  49. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19(5):1350–57.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.